Cantwell A M, Di Cera E
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Biol Chem. 2000 Dec 22;275(51):39827-30. doi: 10.1074/jbc.C000751200.
Thrombin acts as a procoagulant when it cleaves fibrinogen and promotes the formation of a fibrin clot and functions as an anticoagulant when it activates protein C with the assistance of the cofactor thrombomodulin. The dual function of thrombin in the blood poses the challenge to turn the enzyme into a potent anticoagulant by selectively abrogating fibrinogen cleavage. Using functional and structural data, we have rationally designed a thrombin mutant, W215A/E217A, that cleaves fibrinogen with a value of k(cat)/K(m) about 20,000-fold slower than wild-type but activates protein C in the presence of thrombomodulin with a specificity comparable with wild-type. This mutant demonstrates for the first time that the relative specificity of thrombin toward fibrinogen and protein C can be completely reversed.
凝血酶在裂解纤维蛋白原并促进纤维蛋白凝块形成时作为促凝血剂起作用,而在辅因子血栓调节蛋白的协助下激活蛋白C时则作为抗凝血剂发挥作用。凝血酶在血液中的双重功能对通过选择性消除纤维蛋白原裂解将该酶转变为强效抗凝血剂提出了挑战。利用功能和结构数据,我们合理设计了一种凝血酶突变体W215A/E217A,其裂解纤维蛋白原的k(cat)/K(m)值比野生型慢约20,000倍,但在血栓调节蛋白存在下激活蛋白C的特异性与野生型相当。该突变体首次证明凝血酶对纤维蛋白原和蛋白C的相对特异性可以完全逆转。